| Although the infection of hepatitis B virus (HBV) is mainly endemic to sub-Saharan Africa and Asia-Pacific region, now it is gradually becoming an important world-wide public health problem due to the mobility of the population and many-sided fusion around the world. The number of infected persons with chronic HBV has exceeded 350 million, and the risk of dying from HBV-related diseases is about 15% to 25%. Each year about 1 million deaths are commonly associated with complicating cirrhosis, severe hepatitis or hepatocellular carcinoma (HCC). China is the highly infected area in which ten percent populations are infected with HBV and the healths as well as economic problems caused by HBV infection are big problems troubled people. Although recently some effective antiviral drugs have been developed, all of the treatments have their own shortages. The recombinant interferons are suitable to few cases with HBV infection, and the low response efficiencies of patients with IFN in virology result in their limited usage. In addition lamivudine has been shown to have a strong inhibition of HBV replication, but the treatment may be failed due to the drug resistance causing by the escaping... |
PDF Full Text Request